GRA President and CEO Susan Shows to Retire with 22-Year Legacy

Tenure marked by shaping all major aspects of the organization

Susan Shows headshot

A driving factor in the development and success of the Georgia Research Alliance over a tenure that has spanned more than two decades, President and CEO Susan Shows today announced her retirement from the Alliance at the fall meeting of GRA’s Board of Trustees.

Since joining GRA in 2001 as vice president, Shows was instrumental in shaping each of the organization’s areas of operation. She worked closely with member universities to bring top scientific talent to their campuses, playing an active role in the recruitment of most of GRA’s 78-member Academy of Scientists. She also partnered with university leaders to identify “best investments” in high-tech lab equipment and core research facilities to make Georgia’s institutions more competitive in winning lucrative research grants and contracts.

And 20 years ago, she served as chief architect of GRA’s venture development program, a multi-faceted enterprise that has helped launch 240 high-potential startup companies with operations in Georgia, all based on inventions made by university scientists in Georgia.

While serving in the senior vice president role, Shows placed collaboration and impact at the center of these and other activities. She often brokered working partnerships among scientists and universities and between academia and industry. And she developed the statistical framework for providing funders with an accountability of GRA’s performance and its return on the state’s investment in GRA programs.

Since being named president and CEO of GRA in September 2020, Shows has continued to grow GRA’s talent, infrastructure and entrepreneurship programs while also launching several initiatives that leverage university research strengths to address areas of priority for the state.  

“GRA owes so much of its success to Susan, and it would not be the organization it is today without her,” says GRA Board Chair David Ratcliffe. “Her early work in GRA’s program areas was both foundational and durable. As president and CEO, she has brought a new level of agility to the Alliance by creating and seizing opportunities to make an impact in agricultural technology, artificial intelligence, Sickle Cell Disease and workforce development.  And the taxpayers of Georgia should be pleased to know that GRA’s return on investment grew to $13 billion this year.”

Shows will continue to serve in an advisory role until the end of GRA’s fiscal year next June. In reflecting on her tenure with the Alliance, Shows said: “GRA works in so many different ways for the single purpose of growing Georgia’s economy. It has been a great privilege to have been a part of this unique organization, and to have worked on teams of true professionals in government, industry and academia, all to benefit Georgia’s excellent universities and the state as a whole.”

By Maria Thacker Goethe September 5, 2025
Protecting U.S. Leadership in Agricultural Biotechnology
By Maria Thacker Goethe August 29, 2025
Celebrating the Next Generation of Scientific Breakthroughs in Georgia
By Maria Thacker Goethe August 29, 2025
Investment in early-stage life sciences companies is critical to sustain America’s global leadership in discovering and developing new medical breakthroughs for patients, according to a recent General Catalyst blog, “ The Future of Life Sciences Investment .” Early-stage life sciences companies are unique for their ability to leverage specialized scientific knowledge and a nimble structure to pursue new, innovative approaches to treat a disease. However, these companies often rely on external investment, such as from venture capital (VC), to be able navigate the cost pressures and considerable risks associated with early-stage drug development. Life sciences mergers and acquisitions (M&A) represent a clear exit point for VC investors, attracting investment and allowing companies of all sizes to combine their complementary resources, skills and expertise to bring new medicines to patients. Amidst an increasingly challenging investment landscape, preserving M&A is critical to continue supporting the hundreds of pre-clinical companies working to bring new therapies to patients. Highlights from the blog are included below: “Over the past decade, the biopharmaceutical industry has quietly produced a steady drumbeat of significant medical advances…Despite these advances, there’s global pressure to innovate faster. While the U.S. has historically been the global leader in scientific research and development, it now faces increased international competition…” “For America to maintain its competitive advantage, it must continue investing in research and clinical development… We believe that venture capital can meaningfully contribute to fill this investment gap, providing support for America’s continued ability to innovate and advance global human health." “This isn’t just our belief — venture-backed companies are driving enhanced R&D productivity and efficiency. Recent data shows that roughly 65% of new medicines originated from outside of large pharmaceutical companies.” “We believe the most meaningful breakthroughs in life sciences are rarely achieved in isolation. They’re the result of deep, sustained collaboration — between scientists and clinicians, industry and academia, and increasingly, founders and investors.” As this blog highlights, life sciences M&A remains a critical pathway for fueling investment and supporting America’s role as a global leader in life sciences innovation. Policymakers must recognize the value of life science M&A and support enforcement policies that encourage these pro-competitive partnerships and the innovative medicines they bring to patients. About the Partnership for U.S. Life Science Ecosystem (PULSE) The U.S. life sciences ecosystem depends on mergers and acquisitions (M&A) as well as other collaborations to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients. PULSE is dedicated to raising awareness about the unique life sciences ecosystem and the importance of M&A in leveraging efficiency and experience across companies of all sizes. PULSE will help advance a national dialogue focused on fostering innovation across the life sciences while supporting a competitive U.S. market that advances next generation treatments and cures for patients. For more information, visit https://pulseforinnovation.org/.
MORE POSTS